Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03777982
Title A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate cancer

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Beth Israel Deaconess Medical Center Recruiting Boston Massachusetts 02215 United States Details
Brigham and Women's Hospital Recruiting Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center Recruiting Milford Massachusetts 01757 United States Details
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital Recruiting South Weymouth Massachusetts 02190 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field